No Data
No Data
Haizheng Pharmaceutical (600267.SH): 59.315 million restricted shares will be listed and circulated on March 25
Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company's current stock listing type is non-public shares; the stock subscription method is offline, and the total number of shares currently in circulation is 599.315 million shares. The current stock listing circulation date is March 25, 2024.
Retail Investors Are Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Biggest Owners and Were Hit After Market Cap Dropped CN¥488m
Key Insights Significant control over Zhejiang Hisun Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions The to
Haizheng Pharmaceutical (600267.SH): A total cost of 697.16 million yuan to buy back 0.6482% of shares
Gelonghui, March 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of February 29, 2024, the company had repurchased a total of 7,829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 69,716,268.41 yuan.
Haizheng Pharmaceutical (600267.SH): Oseltamivir phosphate API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”
Gelonghui, Feb. 28: Haizheng Pharmaceutical (600267.SH) announced that Haizheng Pharmaceutical Nantong Co., Ltd., a wholly-owned subsidiary, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for oseltamivir phosphate APIs approved and issued by the State Drug Administration on February 28, 2024. Oseltamivir phosphate is a precursor drug for its active metabolite (oseltamivir carboxylate). Oseltamivir carboxylate is a selective influenza virus neuraminidase inhibitor used in the treatment of influenza A and B in adults and children aged 1 year and over, as well as influenza A and B in adults and adolescents aged 13 and over
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
The Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) share price has fared very poorly over the last month, falling by a substantial 27%. The drop over the last 30 days has capped off a tough
Haizheng Pharmaceutical (600267.SH): A total cost of 568.487 million yuan to buy back 0.5% of shares
Gelonghui, January 31, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of January 31, 2024, the company had repurchased a total of 6,111,900 shares, accounting for 0.5060% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.71 yuan/share, and the total amount paid was 56,848,689.65 yuan.
No Data